

FORM PTO-1449  
(REV. 7-80)INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION  
*(Use several sheets if necessary)*ATTY. DOCKET NO.  
KIR92-01A3SERIAL NO.  
08/607,419APPLICANTS Marc Feldmann, Ravinder N. Maini  
and Richard O. WilliamsFILING DATE  
February 28, 1996GROUP  
1806 RECEIVED  
1 SEP 16 1996

## U. S. PATENT DOCUMENTS

EXAM- INER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	GROUP	1500 SUB- CLASS	DATE IF APPROPRIATE
	AA			MAIL ROOM JUN 12 92 1996 PCT & TRADEMARK OFF.				
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	AL	WO 89/08460	21-SEP-89	PCT				
	AM	WO 92/08474	29-MAY-92	PCT				
	AN	WO 92/07585	14-MAY-92	PCT				
	AO							
	AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Horneff, G., et al., "Elevated levels of circulating tumor necrosis factor- $\alpha$ , interferon- $\gamma$ , and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis", <i>Cytokine</i> , 3(3):266-247 (1991).
	AS	Brennan, F., et al., "Inhibitory effect of TNF $\alpha$ antibodies on synovial cell interleukin-1 production in rheumatoid arthritis", <i>The Lancet</i> , 2(8657):244-247 (1989).
	AT	Steinbruchel, D., et al., "Monoclonal antibody treatment (anti-CD4 and anti-interleukin-2 receptor) combined with cyclosporin A has a positive but not simple dose-dependent effect on rat renal allograft survival", <i>Scandinavian J. of Immunol.</i> , 34(5):627-633 (1991).

EXAMINER

Philip Grumbel

DATE CONSIDERED


12/14/97

FORM PTO-1449 (REV. 7-80) INFORMATION DISCLOSURE CITATION IN AN APPLICATION  <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. KIR92-01A3	SERIAL NO. 08/607,419
	APPLICANTS Marc Feldmann, Ravinder N. Maini and Richard O. Williams	
	FILING DATE February 28, 1996	GROUP 1806

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AU	Breedveld, F., et al., "Anti-CD4 antibodies in rheumatoid arthritis", <i>Clinical and Experimental Rheumatology</i> , 10(4): 325-326 (1992). 
	AV	Brennan, F., et al., TNF $\alpha$ -a pivotal role in rheumatoid arthritis?", <i>British J. Rheumatology</i> , 31(5):293-298 (1992).
	AW	Elliott, M.J., et al., "Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF- $\alpha$ : safety, clinical efficacy and control of the acute phase response", <i>Cell. Biochemistry, Supplement</i> , 0(17B):145 (1993); Abstract EZ405.
	AX	Williams, R.O., et al., "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis", <i>Proc. Natl. Acad. Sci. USA</i> , 91:2762-2766 (1994).
	AY	Ralph, P., "Clinical and Preclinical Studies Presented at the Keystone Symposium on Arthritis, Related Diseases, and Cytokines," <i>Lymphokine and Cytokine Research.</i> , 12(4):261-263 (1993).
	AZ	Racadot, E., "Immunological follow-up of 17 patients with rheumatoid arthritis treated <i>in vivo</i> with an anti-T CD4+ monoclonal antibody (B-F5)," <i>Clinical and Experimental Rheumatology</i> , 10:365-374 (1992).
	AR2	Williams, R.O., et al., "Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4," <i>Immunology</i> , 84:433-439 (March 1995).
	AS2	Van Der Lubbe, P.A., et al., "A Randomized, Double-Blind, Placebo-Controlled Study of CD4 Monoclonal Antibody Therapy In Early Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> , 38(8): 1097-1106 (1995).

EXAMINER

Philip Gamble

DATE CONSIDERED

12/4/97

FORM PTO-1449 (REV. 7-80) <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. <b>KIR92-01A3</b>	SERIAL NO. <b>08/607,419</b>			
			APPLICANTS: <b>Marc Feldmann, Ravinder N. Maini and Richard O. Williams</b>				
			FILING DATE <b>February 28, 1996</b>	GROUP <b>1806</b>			
<b>U.S. PATENT DOCUMENTS</b>							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
UC	AT2	Choy, E.H.S., et al., "Therapeutic Monoclonal Antibodies," <i>British J. Rheumatology</i> , 34:707-715 (1995).					
	AU2	Rankin, E.C.C., et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis," <i>British J. Rheumatology</i> , 34: 334-342 (1995). 					
	AV2	Butler, D.M., et al., "Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF- $\alpha$ antibody with the interleukin-1 receptor antagonist," <i>Eur. Cytokine Netw.</i> , 6(4): 225-230 (1995).					
	AW2	Horneff, G., et al., "Treatment of Rheumatoid Arthritis with an Anti-CD4 Monoclonal Antibody," <i>Arthritis &amp; Rheumatism</i> , 34(2): 129-140 (1991).					
	AX2	Van Dullemen, H.M., et al., "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> , 109(1):129-135 (1995).					
	AY2	Watts, R.A., and Isaacs, J.D., "Immunotherapy of rheumatoid arthritis," <i>Annals Rheumatic Diseases</i> , 51:577-579 (1992).					
U	AZ2	Schacht, E., "Gegenwärtige und zukünftige Therapiestrategien der rheumatoïden Arthritis (RA)*) ["The current and future therapy strategies of rheumatoid arthritis (RA)], <i>Zeitschrift für Rheumatologie</i> , 52(6):365-382 (1993). <i>summary only</i>					
EXAMINER <i>PHILIP GRAMBEL</i>			DATE CONSIDERED <i>12/4/97</i>				

FORM PTO-1449 (REV. 7-80)	ATTY. DOCKET NO. <b>KIR92-01A3</b>	SERIAL NO. <b>08/607,419</b>
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		
APPLICANTS <b>Marc Feldmann, Ravinder N. Maini and Richard O. Williams</b>		
FILING DATE <b>February 28, 1996</b>		GROUP <b>1806</b>

U.S. PATENT DOCUMENTS



## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

*12* AR3 Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF $\alpha$ ", *Rev. Esp. Reumatol.*, 20 Suppl. 1:148 (1993); Abstract 320.

EXAMINER

Philip Grimes  
2/4/97

**DATE CONSIDERED**